Precision Cardiovascular Secures Oversubscribed Seven-Figure Funding Round and Second Consecutive Innovate UK Grant

March 15, 2025 06:08 AM AEDT | By EIN Presswire

Google News:

Precision Cardiovascular Secures Oversubscribed Seven-Figure Funding Round and Second Consecutive Innovate UK Grant — Image source: EIN Presswire

Recent News

ASX 200 Drifts Lower as Geopolitical Tensions Over Iran Drive Crude Ma...

Tech Stocks Lead Gains on ASX 200 as Mining Lags

Cicada Innovations CEO Steps Down After Transformational Tenure: What...

Defence and Critical Minerals ASX Stocks Show Notable Trends

Funding Round to Support Pre-Clinical Development of First-in-Class Heart Failure Monitoring Technology LONDON, UNITED KINGDOM, March 14, 2025 /EINPresswire.com/ -- Precision Cardiovascular (PCV), an innovator in minimally invasive cardiac management solutions, has successfully concluded an oversubscribed seven-figure investment round, attracting support from both new and returning private investors. This capital infusion strategically advances the company’s preclinical development initiatives, ensuring the completion of essential large-animal chronic and Good Lab Practice (GLP) studies as PCV progresses toward its First-in-Human (FIH) trials.

In parallel, PCV has secured a second consecutive Innovate UK Biomedical Catalyst grant, marking a historic milestone as the first Class III medical device company to receive consecutive funding from this prestigious national innovation program. This continued support from Innovate UK underscores the potential of PCV’s next-generation haemodynamic monitoring platform and reinforces its trajectory toward critical clinical development milestones.

This funding will enable PCV to:

Complete pre-clinical studies, including long-term chronic and GLP animal studies, to generate robust safety and performance data.

Advance regulatory and clinical readiness, establishing a solid foundation for initiating human trials.

Further develop sensor technology and haemodynamic monitoring capabilities, reinforcing the company’s position as a leader in AI-enhanced cardiac management.

“This investment and continued backing from Innovate UK are significant milestones for Precision Cardiovascular,” said Mohamed Abou-Alam, CEO of PCV. “We are grateful for the confidence shown by our investors and Innovate UK in our mission to bring life-changing, minimally invasive cardiac management solutions to patients with heart failure. With this funding, we are now equipped to execute our pre-clinical strategy and move towards clinical translation.”

About Precision Cardiovascular

Precision Cardiovascular is developing an advanced minimally invasive haemodynamic monitoring system to enable continuous, high-fidelity insights into heart failure physiology and disease progression. By integrating state-of-the-art sensor technology with predictive analytics, PCV is pioneering a new era of proactive and data-driven cardiac care.

For more information visit – www.precision-cv.com

Josh Purchase
Precision Cardiovascular
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.